Targeting Advanced Malignancies with Regional Therapies

Iron Mountain, MI US
September 24, 2014

This educational activity is designed to highlight current issues in the management of patients with peritoneal surface malignancies. Historically, malignant peritoneal mesothelioma (MPM) has been considered an aggressive and lethal neoplasm. However, contemporary series have demonstrated improved outcomes following a combination of cytoreductive surgery and intraperitoneal chemotherapy. There is evidence that suggests patient survival would improve with surgical therapy.

For example, peritoneal dissemination in colorectal cancer patients represents stage IV disease, and therefore it is usually treated with a combination of cytotoxic chemotherapy and biological agents. Currently there is growing evidence to show that just as there is a subset of patients with stage IV disease with liver metastases who have a long-term benefit from the surgical eradication of their metastatic disease, there is a subset of patients with peritoneal dissemination from colon cancer that may benefit from a complete cytoreduction and HIPEC.  

“…the treatment of patients with peritoneal surface malignancies has undergone significant transformational changes with meaningful clinical advances. Current multi-modality therapy combines cytoreductive surgery with peritonectomy procedures to remove all visible tumor, coupled with hyperthermic intraperitoneal chemotherapy
(HIPEC) to eradicate microscopic residual disease. This comprehensive treatment strategy is playing an everincreasing role in the management of patients with colorectal
cancer with peritoneal dissemination. “ K. Turaga et.al. Ann Surg Oncol (2014) 21:1501-1505. 

ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
AMA Credit Designation Statement: 
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of  Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals. 

Target Audience

  • Surgeons

Learning Objectives

At the conclusion of this activitity, participants will be able to demonstrate:

  1. The current evidence behind peritoneal-based therapies
  2. Outcomes of patients undergoing regional therapies
  3. Future research directions in the field
Additional information

CME Coordinator Contact Information

Name: 
Dana Schmidman
Phone Number: 
+1 (414) 805-5602
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
08/19/2014
Course expires: 
11/17/2014
Event starts: 
09/24/2014 - 6:00pm
Event ends: 
09/24/2014 - 8:00pm
Cost:
$0.00
Chippewa Club
106 North Carpenter Avenue
Iron Mountain, MI 49801
United States
Fabian Johnston, MD, MHS
Assistant Professor
Division of Surgical Oncology
Medical College of Wisconsin
 
Kiran Turaga, MD, MPH
Assistant Professor
Division of Surgical Oncology
Medical College of Wisconsin
 

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following:

NameCompanyRole
Kiran Turaga, MD, MPHCastle BiosciencesSpeaker
 EthiconConsultant

In accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
08/19/2014
Course expires: 
11/17/2014

Price

Cost:
$0.00
Please login or register to take this course.